BioSyent logo.png
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
10. April 2024 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton &...
BioSyent logo.png
FeraMAX® est la marque de supplément de fer que les pharmaciens et les médecins au Canada recommandent le plus souvent depuis neuf années consécutives
03. April 2024 08:00 ET | BioSyent Inc.
Mississauga (Ontario), 03 avr. 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », titre à la Bourse de croissance TSX : RX) est fière d’annoncer que FeraMAXMD est la marque de supplément de fer...
BioSyent logo.png
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
03. April 2024 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 03, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based...
BioSyent logo.png
BioSyent to Present at LD Micro New York Investor Conference
01. April 2024 14:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that Mr. René Goehrum, President and CEO of BioSyent, will be...
BioSyent logo.png
BioSyent Announces Grant of Restricted Share Units
27. März 2024 18:34 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020...
BioSyent logo.png
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023
13. März 2024 17:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
BioSyent logo.png
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
06. März 2024 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent logo.png
BioSyent Named to 2024 TSX Venture 50
21. Februar 2024 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as...
BioSyent logo.png
BioSyent Declares First Quarter 2024 Dividend
06. Februar 2024 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent logo.png
BioSyent Announces Renewal of Normal Course Issuer Bid
13. Dezember 2023 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario , Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...